A triple agonist of the GIP, GLP-1 and glucagon receptors.
PRODUCT PROFILE
Retatrutide
Price range: £49.99 through £209.99
Retatrutide is an experimental medicine designed to activate three hormone signals involved in appetite, blood-sugar control and energy use. Researchers are studying whether combining all three signals can produce different metabolic effects from medicines that target only one or two.
Why it is distinct
It is the only triple-receptor agonist in this catalogue: GIP, GLP-1 and glucagon.
- Evidence stagePhase 3 clinical research
- AvailabilityAvailable · 20 in stock
- Batch recordPublished after verification
- DispatchConfirmed at checkout
PRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
Retatrutide is an experimental medicine designed to activate three hormone signals involved in appetite, blood-sugar control and energy use. Researchers are studying whether combining all three signals can produce different metabolic effects from medicines that target only one or two.
Research focus+
Clinical research examines weight change, appetite, blood-sugar control and other metabolic measures. Its glucagon-receptor activity is the main addition beyond tirzepatide.
How the mechanism differs+
It activates three metabolic receptors. GLP-1 and GIP affect appetite and glucose signalling, while glucagon-receptor activity adds a different energy-use pathway.
Evidence and limitations+
Published phase 2 obesity data and ongoing phase 3 programmes exist. It remains investigational and is not authorised for sale as a medicine.
Testing and batch documentation+
No live certificate is shown for this staging item. ADINA will only publish a batch document after the product identifier, test method and result have been checked.
RESEARCH PROFILE
Understand the distinction.
Clinical research examines weight change, appetite, blood-sugar control and other metabolic measures. Its glucagon-receptor activity is the main addition beyond tirzepatide.
It activates three metabolic receptors. GLP-1 and GIP affect appetite and glucose signalling, while glucagon-receptor activity adds a different energy-use pathway.
It is the only triple-receptor agonist in this catalogue: GIP, GLP-1 and glucagon.
Published phase 2 obesity data and ongoing phase 3 programmes exist. It remains investigational and is not authorised for sale as a medicine.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Established
Tirzepatide
£79.0010 mgBatch file pendingDual incretin agonism distinguishes it from single-target semaglutide and triple-target retatrutide.
UnavailableAsk about availability -
Clinical research
Cagrilintide
£64.005 mgBatch file pendingTargets amylin biology, making it mechanistically distinct from every incretin agonist in the category.
UnavailableAsk about availability -
Established
Semaglutide
£69.005 mgBatch file pendingA single-pathway GLP-1 comparator rather than a dual or triple incretin agonist.
UnavailableAsk about availability -
Phase 2 clinical research
MOTS-c
£35.64Batch file pendingMOTS-c begins inside mitochondria and is studied for cell-wide energy adaptation, rather than directly targeting appetite receptors.
Available · 30 in stockAdd to basket